MedPath

Bristol Myers Squibb Announces Positive Data for Sotyktu in Moderate to Severe Psoriasis

Bristol Myers Squibb has revealed encouraging results from a phase 3b/4 study of Sotyktu, an oral TYK2 inhibitor, for treating moderate-to-severe scalp psoriasis. The study showed significant improvements in scalp-specific Physician’s Global Assessment response and Psoriasis Scalp Severity Index, with Sotyktu outperforming placebo. The findings were presented at the European Academy of Dermatology and Venereology Congress, highlighting Sotyktu's potential as a systemic therapy for psoriasis, particularly in cases involving the scalp.

Bristol Myers Squibb (BMS) has announced positive results from a phase 3b/4 study of its oral TYK2 inhibitor Sotyktu (deucravacitinib) in moderate-to-severe scalp psoriasis. The data, presented at this year’s European Academy of Dermatology and Venereology Congress, comes from the ongoing PSORIATYK SCALP trial. This trial included patients with less extensive overall psoriasis.
  • Primary Endpoint: The study met its primary endpoint, with 48.5% of patients achieving a scalp-specific Physician’s Global Assessment response of zero or one (clear/almost clear) at week 16, compared to 13.7% on placebo.
  • Key Secondary Endpoints: At week 16, a significantly higher percentage of patients achieved at least a 90% improvement in Psoriasis Scalp Severity Index response and a notable change from baseline in scalp-specific itch with Sotyktu treatment compared to placebo.
Psoriasis affects at least 100 million people worldwide, causing inflammation in the body. Scalp psoriasis occurs in approximately 80% of patients with plaque psoriasis, the most common form of the condition, and is associated with itching, flaking, pain, and bleeding.
Sotyktu is already approved in major markets for treating certain patients with moderate-to-severe plaque psoriasis, having shown in late-stage trials to improve skin clearance, symptom burden, and quality of life.
Additionally, BMS presented positive data from its Registry of Psoriasis Health Outcomes: A Longitudinal Real-World Collaboration Study (RePhlect) involving 118 patients, 108 of whom had moderate-to-severe plaque psoriasis. The analysis found that the effectiveness of continuous Sotyktu treatment after six months in real-world registry patients was consistent with efficacy outcomes observed in the POETYK PSO clinical studies.
Daniel Quirk, senior vice president, worldwide immunology and neuroscience medical affairs at BMS, commented on the results: “This data further demonstrates the safety and efficacy of Sotyktu for the treatment of psoriasis in high-impact areas, such as the scalp… We believe Sotyktu has the potential to be the systemic therapy that healthcare providers turn to when treating adult patients with moderate-to-severe psoriasis, especially those with scalp involvement.”
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

BMS's Sotyktu Demonstrates Success in Phase III Psoriatic Arthritis Trials

Bristol Myers Squibb's Sotyktu has achieved positive results in two Phase III clinical trials for psoriatic arthritis, marking a significant advancement in treatment options for this chronic inflammatory condition. This development expands the potential therapeutic applications of Sotyktu beyond its existing indications.

Sotyktu Meets Primary Endpoints in Phase 3 Psoriatic Arthritis Trials

Bristol Myers Squibb's Sotyktu (deucravacitinib) demonstrated significant efficacy in two Phase 3 trials for active psoriatic arthritis (PsA).
The POETYK PsA-1 and PsA-2 trials met their primary endpoint, showing a greater proportion of Sotyktu-treated patients achieved ACR20 response at Week 16 compared to placebo.

HyBryte Shows Sustained Improvement in CTCL Lesions Post-Treatment

Soligenix's HyBryte demonstrated continued improvement in cutaneous T-cell lymphoma (CTCL) lesions even after treatment cessation.
A comparative study showed a statistically significant improvement in plaque lesion response with HyBryte versus Valchlor at week 16 (p=0.006).

Icotrokinra Shows Promise in Phase 3 Trials for Plaque Psoriasis

Icotrokinra, an oral peptide targeting the IL-23 receptor, met primary endpoints in two Phase 3 trials for moderate-to-severe plaque psoriasis.
The ICONIC-LEAD trial demonstrated that 64.7% of patients achieved clear or almost clear skin at week 16, significantly higher than placebo.

Icotrokinra Shows Promise as Oral Treatment for Plaque Psoriasis in Phase 3 Trial

Icotrokinra, an oral peptide drug blocking the IL-23 receptor, demonstrated significant clearance of psoriatic plaques in a Phase 3 trial.
65% of patients achieved clear skin (IGA score of 0 or 1) at week 16 with icotrokinra, compared to 8% in the placebo group.

GSK's Linerixibat Shows Positive Phase III Results for Cholestatic Pruritus in PBC

GSK's linerixibat met the primary endpoint in the GLISTEN phase III trial, demonstrating a statistically significant reduction in itch for PBC patients.
The trial included PBC patients with moderate to severe itch, already on stable doses of guideline-suggested therapies, treatment-naïve, or previously treated.

J&J's Oral IL-23 Inhibitor Icotrokinra Achieves Positive Phase 3 Results in Psoriasis

Johnson & Johnson's icotrokinra met primary endpoints in the ICONIC-LEAD phase 3 trial, demonstrating significant skin clearance in psoriasis patients.
After 16 weeks, 64.7% of patients achieved clear or almost clear skin (IGA 0/1), and 49.6% showed a 90% or greater improvement in PASI score.

Icotrokinra Shows Promising Phase 3 Results for Moderate to Severe Plaque Psoriasis

Johnson & Johnson's icotrokinra (JNJ-2113), a novel oral IL-23 receptor antagonist, met its co-primary endpoints in Phase 3 trials for moderate to severe plaque psoriasis.
The ICONIC-LEAD study showed 74.1% of patients achieved clear or almost clear skin (IGA 0/1) at week 24, with 64.9% achieving PASI 90.

Abbisko's Pimicotinib Shows Promise in Phase 3 Trial for Tenosynovial Giant Cell Tumor

Pimicotinib, an oral drug developed by Abbisko Therapeutics, demonstrated a 54% tumor shrinkage rate in patients with tenosynovial giant cell tumor (TGCT).
The Phase 3 MANEUVER study evaluated pimicotinib against placebo in patients with TGCT who had not received prior CSF-1R inhibitor treatment.

InnoCare's TYK2 Inhibitor ICP-488 Demonstrates Promising Phase II Results in Psoriasis Patients

InnoCare's ICP-488, a TYK2 inhibitor, met its primary endpoint in a Phase II trial for moderate-to-severe plaque psoriasis, showing significant improvements in PASI scores.
The study, involving 129 Chinese adults, demonstrated that ICP-488 at 6mg and 9mg daily dosages led to substantial PASI 75, 90, and 100 responses compared to placebo.

Reference News

[1]
Bristol Myers Squibb announces positive data for Sotyktu in ...
pmlive.com · Oct 2, 2024

Bristol Myers Squibb's Sotyktu showed positive results in treating moderate-to-severe scalp psoriasis in the PSORIATYK S...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy